Cerebrolysin vs Semax
A side-by-side research comparison of Cerebrolysin and Semax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Semax |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Semax (ACTH 4-10 analog) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | Activates MC3/4R, increases BDNF and NGF, modulates dopamine/serotonin, enhances neuronal survival via TrkB, and promotes CREB-mediated neuroplasticity. |
| Molecular weight | <10,000 Da (peptide fraction) | 813.9 Da |
| Half-life | 4-6 hours | 3-5 min (systemic) / extended (intranasal) |
| Bioavailability | High (IM/IV) | Moderate (intranasal) |
| Typical dose | 5-30 mL | 200-600 mcg per dose |
| Frequency | Daily for 10-20 days | 2-3x daily |
| Route | Intramuscular or IV | Intranasal drops/spray |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Semax reported benefits
- Enhanced attention/focus
- Memory improvement
- Neuroprotection (stroke)
- BDNF/NGF upregulation
- Improved learning
- Optic nerve support
Related comparisons
Research and educational reference only. Not medical advice.